Driven By Herceptin Franchise, Roche Hopes Rituxan Will Follow Suit
This article was originally published in The Pink Sheet Daily
The Swiss pharma reported a positive start to the year with its first quarter earnings on April 11, underscoring the strength of its oncology products as it continues to work on lifecycle management.
You may also be interested in...
Roche Sees Access Programs As Key To Growth In China, Brazil: Emerging Market Earnings Roundup (Part 1)
With biosimilars on the horizon, the Swiss pharma cites Herceptin and MabThera as key growth drivers in emerging markets.
With new drugs at hand to protect its Herceptin breast cancer franchise, Roche announced positive data for its rituximab replacement candidate and other steps in its plan to protect top-seller Rituxan/MabThera.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.